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Abstract
Background: Studies have shown that industry-sponsored meta-analyses of drugs lack scientific rigour and have
biased conclusions. However, these studies have been restricted to certain medical specialities. We compared all
industry-supported meta-analyses of drug-drug comparisons with those without industry support.
Methods: We searched PubMed for all meta-analyses that compared different drugs or classes of drugs published
in 2004. Two authors assessed the meta-analyses and independently extracted data. We used a validated scale for
judging the methodological quality and a binary scale for judging conclusions. We divided the meta-analyses
according to the type of support in 3 categories: industry-supported, non-profit support or no support, and
undeclared support.
Results:  We included 39 meta-analyses. Ten had industry support, 18 non-profit or no support, and 11
undeclared support. On a 0–7 scale, the median quality score was 6 for meta-analyses with non-profit or no
support and 2.5 for the industry-supported meta-analyses (P < 0.01). Compared with industry-supported meta-
analyses, more meta-analyses with non-profit or no support avoided bias in the selection of studies (P = 0.01),
more often stated the search methods used to find studies (P = 0.02), searched comprehensively (P < 0.01),
reported criteria for assessing the validity of the studies (P = 0.02), used appropriate criteria (P = 0.04), described
methods of allocation concealment (P = 0.05), described methods of blinding (P = 0.05), and described excluded
patients (P = 0.08) and studies (P = 0.15). Forty percent of the industry-supported meta-analyses recommended
the experimental drug without reservations, compared with 22% of the meta-analyses with non-profit or no
support (P = 0.57).
In a sensitivity analysis, we contacted the authors of the meta-analyses with undeclared support. Eight who replied
that they had not received industry funding were added to those with non-profit or no support, and 3 who did
not reply were added to those with industry support. This analysis did not change the results much.
Conclusion: Transparency is essential for readers to make their own judgment about medical interventions
guided by the results of meta-analyses. We found that industry-supported meta-analyses are less transparent than
meta-analyses with non-profit support or no support.
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Background
The primary source of knowledge used by physicians is
the medical literature [1]. The amount of information on
health care interventions is hardly manageable, however,
and the need for systematic reviews and meta-analyses to
aggregate the information and give a basis for rational
decision-making is therefore obvious [2]. Systematic
reviews and meta-analyses of randomised controlled trials
are considered to be the highest level of evidence [3].
Bias in industry-sponsored drug trials is common and the
sponsor's product is often favoured [4-7]. Concerning sys-
tematic reviews and meta-analyses, little information has
been available on sponsor bias until recently. We found
that, although the results were similar, industry-supported
meta-analyses lacked scientific rigour and were more
likely to recommend the experimental drug, compared to
Cochrane reviews of the same disease and drugs [8]. A
study on anti-hypertensive drugs found that meta-analy-
ses with financial ties to only one drug company were
associated with conclusions in favour of that company
[9].
For this report, we assessed all meta-analyses indexed on
PubMed of drug-drug comparisons published in 2004.
We hypothesized that meta-analyses supported by the
pharmaceutical industry are of poorer methodological
quality and have conclusions favouring the experimental
drug, compared to meta-analyses with non-profit or no
support.
Methods
We collected meta-analyses that compared different drugs
or classes of drugs, were published in full and in English.
A meta-analysis was defined as a review with quantita-
tively combined data from at least two studies. Meta-anal-
yses that we had authored ourselves and meta-analyses of
placebo controlled trials were excluded.
Literature search
We searched PubMed for meta-analyses published in
2004 in English. We used a validated search strategy [10]
and combined it with "Drug Therapy" [MeSH] OR "drug
therapy" [Subheading] OR "Pharmaceutical Preparations"
[MeSH] OR "drugs".
One author (KLM) reviewed the titles and abstracts of all
potentially eligible meta-analyses, and if in doubt, the full
text of the article was retrieved. Another author (AWJ)
assessed all the included and 10% of the excluded meta-
analyses for eligibility. Disagreements were resolved by
discussion.
Data extraction
Two authors independently assessed the included meta-
analyses. Data extraction was done unblinded. A third
author resolved disagreements.
We used a pilot tested data sheet and extracted data on
drugs and diseases; types of support; sources used to iden-
tify trials for the review; searches for unpublished trials;
and descriptions of concealment of allocation, details of
blinding, and excluded patients and trials.
We assessed the methodological quality of the reviews
with the Oxman and Guyatt index, which is a validated
tool with nine items considering the potential for bias and
an overall assessment on a 0–7 scale [11-13]. Further-
more, we judged the review authors' conclusions by
assessing whether the experimental intervention was rec-
ommended without reservations, or whether it was not
recommended (or recommended with reservations) [6].
Data analysis
We divided the meta-analyses according to the type of
support in 3 categories: industry-supported, non-profit
support or no support, and undeclared support.
Industry support was defined as authorship, provision of
grants to authors of the meta-analysis, or other major
assistance such as help with the statistical analysis. We did
not consider provision of references or unpublished trial
reports as support.
We compared industry-supported meta-analyses with
meta-analyses with non-profit support or no support with
the Mann-Whitney test for categorical data and with
Fisher's exact test for binary data; P values are two-sided.
Results
The search in PubMed identified 1188 records of meta-
analyses. Most were ineligible because they did not com-
pare drugs (Figure 1). We included 39 meta-analyses, 10
of which were Cochrane reviews. Ten had industry sup-
port, 18 non-profit or no support, and 11 undeclared sup-
port (Table 1 and additional file 1: References of included
meta-analyses).
Methodological quality
The median quality score was 6 for the 18 meta-analyses
with non-profit or no support and 2.5 for the ten industry-
supported meta-analyses (P < 0.01) (Table 2). More meta-
analyses with non-profit or no support avoided bias in the
selection of studies (P = 0.01); only five industry-sup-
ported meta-analyses reported specific inclusion criteria
and two only included studies provided by the supporting
company. Meta-analyses with non-profit or no support
more often stated the search methods used to find studiesBMC Medical Research Methodology 2008, 8:60 http://www.biomedcentral.com/1471-2288/8/60
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(P = 0.02) and searched comprehensively (P < 0.01). Only
four (40%) industry-supported meta-analyses searched
for unpublished studies and five (50%) searched in the
Cochrane Library and MEDLINE. For meta-analyses with
non-profit or no support the numbers were 16 (89%) and
14 (78%) respectively. Meta-analyses with non-profit or
no support more often reported criteria for assessing the
validity of the studies (P = 0.02), used appropriate criteria
(P = 0.04), described methods of allocation concealment
(P = 0.05), described methods of blinding (P = 0.05), and
Table 1: Characteristics of included meta-analyses.
Search strategy incl. Detailed description of
Ref # Medline 
and CLIB
Unpublishe
d studies
Allocation 
concealment
Blinding Excluded 
patients
Excluded 
studies
Recommends the 
experimental 
drug without 
reservations
Quality 
score
Industry 
support
1 ✔✔ ✔ 4
2 ✔✔ 2
3 ✔ 2
4 ✔✔ ✔ 3
5 ✔✔ ✔ 4
6 ✔ 2
7 ✔ 1
8 ✔ ✔ 2
9 ✔✔ 3
10 ✔ 6
Non-profit 
or no 
support
11 ✔ 2
12 ✔✔ ✔ 3
13 ✔✔ ✔ ✔ 3
14 ✔✔ ✔ ✔ 6
15 ✔✔ 3
16 ✔✔ ✔ 4
17 ✔✔ ✔ ✔ 7
18 ✔✔ 5
19 ✔✔ ✔ ✔ 6
20 ✔✔ ✔ 3
21 ✔✔ ✔ ✔ ✔ 7
22 ✔✔ ✔✔ ✔ ✔ 7
23 ✔✔ ✔✔ ✔ ✔ 7
24 ✔✔ ✔✔ ✔ 6
25 ✔✔ ✔ ✔ ✔ 7
26 ✔✔ ✔✔ ✔ ✔ 7
27 ✔✔ ✔✔ ✔ ✔ 6
28 ✔✔ ✔ 6
Support not 
declared
29 ✔✔ 5
30 3
31 2
32 ✔✔ ✔ ✔ ✔ 5
33 ✔✔ 3
34 ✔✔ 3
35 ✔ 2
36 1
37 ✔ 3
38 ✔✔ ✔ ✔ 3
39 ✔✔ 2
CLIB: The Cochrane LibraryBMC Medical Research Methodology 2008, 8:60 http://www.biomedcentral.com/1471-2288/8/60
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described excluded patients (P = 0.08) and studies (P =
0.15).
Authors' conclusion
Four industry-supported meta-analyses (40%) recom-
mended the experimental drug without reservations, com-
pared with four meta-analyses with non-profit or no
support (22%) (P = 0.57). The supporting companies of
all 4 meta-analyses that were recommending the experi-
mental drug without reservation were also selling the
drug, but not the control drug. This only applied to 3 of
the 6 industry-supported meta-analyses that did not rec-
ommend or only recommended the experimental drug
with reservations.
Post hoc sensitivity analyses
We did two sensitivity analyses. First, we excluded the 10
Cochrane reviews from the analysis, as these reviews had
high quality scores (median of 7); nine from the meta-
analyses with non-profit or no support and one from
those with industry support. This resulted in a median
quality score of 3 and 2 respectively (P = 0.06).
Second, we contacted the authors of the 11 meta-analyses
with undeclared support. Four declared that they had not
received any external funding or other type of support
(which we exemplified as help with the statistical analy-
ses), four replied that they had received funding from not-
profit organisations and three did not reply. We added the
eight who replied to the meta-analyses with non-profit or
no support and the three who did not reply to the meta-
Search for meta-analyses and reasons for exclusion Figure 1
Search for meta-analyses and reasons for exclusion.BMC Medical Research Methodology 2008, 8:60 http://www.biomedcentral.com/1471-2288/8/60
Page 5 of 7
(page number not for citation purposes)
analyses with industry support. This sensitivity analysis
did not change the results much, e.g. the median quality
score was 5 for meta-analyses with non-profit or no sup-
port and 2 for industry-supported meta-analyses (P <
0.01)
Discussion
We found that meta-analyses with non-profit or no sup-
port are of better methodological quality on average than
those with industry support. Lack of allocation conceal-
ment and blinding, and high attrition rates in randomised
controlled trials may bias results of meta-analyses, but if
the authors fail to describe these details, the reader is not
able to judge if the meta-analysis is reliable. Most indus-
try-supported meta-analyses failed on these counts; this
agrees with results we have published previously [8].
Cochrane reviews
Cochrane reviews seem to have a better methodological
quality on average than other meta-analyses [8,14-17].
In this study, ten Cochrane reviews contributed with high
methodological quality mainly to meta-analyses with
non-profit or no support, as only one Cochrane review
was supported by the industry. The policy in the Cochrane
Collaboration is that industry support of Cochrane
reviews is not allowed [18].
Forty percent of the industry-supported meta-analyses
and 22 percent of those with non-profit or no support rec-
ommended the experimental drug without reservation.
This difference was not statistically significant, but we
have previously found a significant difference in a com-
parison that was closely matched for drugs and diseases (P
< 0.01) [8]. A large survey of 124 meta-analyses of anti-
hypertensive drugs found that those with financial ties to
only one drug company were significantly associated with
conclusions in favour of that company [9].
Studies of trials have found similar results. A survey found
that none of 56 trial reports of non-steroidal anti-inflam-
matory drugs supported by the manufacturer presented
results that were unfavourable to the company [19].
Another survey found that trials funded by for profit
organizations were more likely to recommend the experi-
mental drug as the drug of choice (odds ratio = 5.3) com-
pared with trials funded by non-profit organisations [6].
And recently a study of randomised trials of head-to-head
comparisons of statins with other drugs found that not
only the conclusions but also the results were in favour of
the sponsor's product [7].
Limitations
We were not blinded, as the layout of some papers, e.g.
Cochrane reviews, is unique and impossible to blind.
Table 2: Methodological quality of meta-analyses. 
Questions Supported by industry Non-profit support or no support P value* Undeclared support
(N = 10) (N = 18) (N = 11)
1. Were the search methods used to find 
evidence on the primary question stated?
61 8 0 . 0 2 6
2. Was the search for evidence 
reasonably comprehensive?
4 17 <0.01 6
3. Were the criteria used for deciding 
which studies to include reported?
5 17 0.03 10
4. Was bias in the selection of studies 
avoided?
11 2 0 . 0 1 3
5. Were the criteria used for assessing 
the validity of the included studies 
reported?
31 5 0 . 0 2 5
6. Was the validity of all studies referred 
to in the text assessed using appropriate 
criteria?
11 0 0 . 0 4 1
7. Were the methods used to combine 
the findings of the relevant studies 
reported?
9 17 1.00 10
8. Were the findings of the relevant 
studies combined appropriately?
71 6 0 . 4 6 8
9. Were the conclusions made by the 
author(s) supported by the data 
reported?
91 5 1 . 0 0 9
Overall quality (1–7) (median score) 2.5 6 <0.01 3
Number of meta-analyses that obtained an affirmative answer to the questions of the Oxman and Guyatt index; and median overall quality score.
* Supported by industry vs non-profit or no support.BMC Medical Research Methodology 2008, 8:60 http://www.biomedcentral.com/1471-2288/8/60
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However, blinding when assessing meta-analyses has little
impact [20].
A substantial part of the meta-analyses with non-profit or
no support were Cochrane reviews and these are made
according to the Cochrane Handbook [21]. Andy Oxman
participated in the development of the validated index
that was used for evaluating methodological quality and
he has also participated in developing the Cochrane
Handbook.
Our definition of industry support does not distinguish
between different amounts of support, and our judge-
ment of support is based on details reported in the meta-
analyses. This can theoretically lead to misclassification of
the support, as industry support may range from very little
to generous, and details about some types of support may
be lacking more often than others. However, the defini-
tion is operational and we believe that it includes the
most important types of industry support. Lack of details
or transparency in meta-analyses may also have led to
misjudgement of the methodological quality, and it has
been argued that the methodological superiority of
Cochrane reviews can be explained by the fact that there
are no word limits in the Cochrane Library. However, the
methodological quality of Cochrane reviews published in
regular journals do not seem to differ from Cochrane
reviews published in The Cochrane Library [16,17]. Fur-
thermore, important methodological details should
always be made available in journals with a word limit,
either in the article itself, or in material on the journal's
website.
Conclusion
Transparency is essential for readers to make their own
judgment about medical interventions guided by the
results of meta-analyses. We found that industry-sup-
ported meta-analyses are less transparent than meta-anal-
yses with non-profit support or no support.
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